Treatment of hypertrophic cardiomyopathy: new methods

Автор: Kasimova Nikhola Kadirovna

Статья в выпуске: 1 (13), 2022 года.

Бесплатный доступ

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle becomes abnormally thick (hypertrophied). The thickened heart muscle can make it harder for the heart to pump blood. Hypertrophic cardiomyopathy often goes undiagnosed because many people with the disease have few, if any, symptoms and can lead normal lives with no significant problems. However, in a small number of people with HCM, the thickened heart muscle can cause shortness of breath, chest pain or problems in the heart's electrical system, resulting in life-threatening abnormal heart rhythms (arrhythmias) or sudden death. Currently, a number of studies are being conducted by scientists and new methods of treating this disease are being developed. We will discuss this in this article.

Еще

Hypertrophic cardiomyopathy, the heart's electrical system, arrhythmias

Короткий адрес: https://sciup.org/14124636

IDR: 14124636

Список литературы Treatment of hypertrophic cardiomyopathy: new methods

Zampieri, M., Berteotti, M., Ferrantini, C., Tassetti, L., Gabriele, M., Tomberli, B., … Olivotto, I. (2021). Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. Current Heart Failure Reports, 18(4), 169–179. doi:10.1007/s11897-021-00523-0.
Spirito, P., Seidman, C. E., McKenna, W. J., &Maron, B. J. (1997). The Management of Hypertrophic Cardiomyopathy. New England Journal of Medicine, 336(11), 775–785. doi:10.1056/nejm199703133361107.
Ma H, Marti-Gutierrez N, Park SW, Wu J, Lee Y, Suzuki K, et al. Correction of a pathogenic gene mutation in human embryos. Nature. 2017.
Jiang J, Wakimoto H, Seidman JG, Seidman CE. Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science. 2013;80.
Sinagra G, Carriere C, Clemenza F, Minà C, Bandera F, Zaffalon D, et al. Risk stratification in cardiomyopathy. Eur J Prev Cardiol. 2020;27:52–8.
Coppini R, Ferrantini C, Mugelli A, Poggesi C, Cerbai E. Altered Ca2+ and Na+ homeostasis in human hypertrophic cardiomyopathy: implications for arrhythmogenesis. Front Physiol. 2018;9.
Coppini R, Santini L, Olivotto I, Ackerman MJ, Cerbai E. Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy. Cardiovasc Res. 2020.
Olivotto I, Coppini R. Channelopathies, cardiac hypertrophy, and the theory of light. Eur Heart J. 2018;39:2908–10.
Nánási PP, Pueyo E, Virág L. Editorial: perspectives of antiarrhythmic drug therapy: disappointing past, current efforts, and faint hopes. Front Pharmacol. 2020;11. 86. Chung MK, Refaat M, Shen WK, Kutyifa V, Cha YM, Di Biase L, et al. Atrial fibrillation: JACC council perspectives. J Am Coll Cardiol. 2020;75:1689–713.
Fumagalli C, De Gregorio MG, Zampieri M, Fedele E, Tomberli A, Chiriatti C, et al. Targeted medical therapies for hypertrophic cardiomyopathy. Curr Cardiol Rep. 2020.
Sisakian H. Cardiomyopathies: evolution of pathogenesis concepts and potential for new therapies. World J Cardiol. 2014;6:478–94.
Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F, et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation. 2013.
Emerging Medical Treatment for Hypertrophic Cardiomyopathy by Alessia Argirò, Mattia Zampieri, Martina Berteotti, Alberto Marchi, Luigi Tasset, Chiara Zocchi, Luisa Iannone, Beatrice Bacchi, Francesco Cappelli, Pierluigi Stefàno ,Niccolò Marchionni Olivotto.
Pelliccia, F.; Alfieri, O.; Calabrò, P.; Cecchi, F.; Ferrazzi, P.; Gragnano, F.; Kaski, J.P.; Limongelli, G.; Maron, M.; Rapezzi, C.; et al. Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team. Int. J. Cardiol. 2020, 304, 86–92.
Preventative therapeutic approaches for hypertrophic cardiomyopathy. Tanya Solomon, Aleksandra Filipovska, Livia Hool, Helena Viola. doi: 10.1113/JP279410. 21 August 2020.
Seidman CE, Seidman JG. Gene mutations that cause familial hypertrophic cardiomyopathy. In: Haber E, ed. Molecular cardiovascular medicine. New York: Scientific American, 1995:193-209.
Thierfelder L, Watkins H, MacRae C, et al. a-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994;77:701-12.
Watkins H, Anan R, Coviello DA, Spirito P, Seidman JG, Seidman CE. A de novo mutation in atropomyosin that causes hypertrophic cardiomyopathy. Circulation 1995;91:2302-5.
Watkins H, Conner D, Thierfelder L, et al. Mutations in the cardiacmyosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995;11:434-7.
Bonne G, Carrier L, Bercovici J, et al. Cardiac myosin binding proteinC gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 1995;11:438-40
Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;58:e212–e260.
Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733–2779.
Seferovic PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, Felix SB, Arbustini E, Caforio ALP, Farmakis D, Filippatos GS, Gialafos E, Kanjuh V, Krljanac G, Limongelli G, Linhart A, Lyon AR, Maksimovic R, Milicic D, Milinkovic I, Noutsias M, Oto A, Oto O, Pavlovic SU, Piepoli MF, Ristic AD, Rosano GM, Seggewiss H, Asanin M, Seferovic JP, Ruschitzka F, Celutkiene J, Jaarsma T, Mueller C, Moura B, Hill L, Volterrani M, Lopatin Y, Metra M, Backs J, Mullens W, Chioncel O, de Boer RA, Anker S, Rapezzi C, Coats AJ, Tschope C. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:553–576.
Spoladore R, Maron MS, D’Amato R, Camici PG, Olivotto I. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J 2012;33:1724–1733.
Cherian G, Brockington IF, Shah PM, Oakley CM, Goodwin JF. Beta-adrenergic blockade in hypertrophic obstructive cardiomyopathy. Br Med J 1966;1:895–898.

Еще

Статья научная